<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3355">
  <stage>Registered</stage>
  <submitdate>12/10/2011</submitdate>
  <approvaldate>12/10/2011</approvaldate>
  <nctid>NCT01472003</nctid>
  <trial_identification>
    <studytitle>An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types</studytitle>
    <scientifictitle>An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types Likely to Express Epidermal Growth Factor Receptor (EGFR)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>M11-849</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced Solid Tumors</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ABT-806
Treatment: drugs - ABT-806i

Experimental: ABT-806 Arm - Subjects with advanced solid tumors

Experimental: ABT-806i Arm - Subjects with advanced solid tumors


Treatment: drugs: ABT-806
ABT-806 will be administered by intravenous infusion.

Treatment: drugs: ABT-806i
ABT-806i will be administered by intravenous infusion.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Single-Photon Emission Computerized Tomography (SPECT) - Tumor receptor occupancy (Cohort 1 and Cohort 2)</outcome>
      <timepoint>Week 1</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Single-Photon Emission Computerized Tomography (SPECT) - Tumor receptor occupancy (Cohort 2)</outcome>
      <timepoint>Week 6</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Whole body planar imaging - Biodistribution and dosimetry (Cohort 1 and Cohort 2)</outcome>
      <timepoint>Week 1</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Whole body planar imaging - Biodistribution and dosimetry (Cohort 2)</outcome>
      <timepoint>Week 6</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic profile evaluation - Cohort 1 - Blood samples for ABT-806/ABT-806i will be collected and assayed at designated timepoints</outcome>
      <timepoint>From Day 1 through Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic profile evaluation - Cohort 2 - Blood samples for ABT-806/ABT-806i will be collected and assayed at designated timepoints</outcome>
      <timepoint>From Day 1 through Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Single-Photon Emission Computerized Tomography (SPECT) - ABT-806i uptake correlation with Epidermal Growth Factor Receptor (EGFR) vIII expression - Cohort 2</outcome>
      <timepoint>Week 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Single-Photon Emission Computerized Tomography (SPECT) - ABT-806i uptake correlation with EGFR vIII expression - Cohort 2</outcome>
      <timepoint>Week 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Whole body planar imaging - ABT-806i uptake correlation with Epidermal Growth Factor Receptor (EGFR) vIII expression - Cohort 2</outcome>
      <timepoint>Week 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Whole body planar imaging - ABT-806i uptake correlation with EGFR vIII expression - Cohort 2</outcome>
      <timepoint>Week 6</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood pressure - Cohort 1</outcome>
      <timepoint>Screening through Week 2</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Heart rate - Cohort 1</outcome>
      <timepoint>Screening through Week 2</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Body temperature - Cohort 1</outcome>
      <timepoint>Screening through Week 2</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of subjects with Adverse Events - Cohort 1 - The investigator will monitor each subject for clinical and laboratory evidence of adverse events.</outcome>
      <timepoint>Day 1 Through Week 2</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Chemistry - Cohort 1</outcome>
      <timepoint>Sceening, Week 1 and Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hematology - Cohort 1</outcome>
      <timepoint>Sceening, Week 1 and Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Urinalysis - Cohort 1</outcome>
      <timepoint>Sceening, Week 1 and Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Physical Examination - Cohort 1 - Physical exam including body weight will be performed.</outcome>
      <timepoint>Screening, Week 1 and Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Electrocardiogram (ECG) - Cohort 1 - 12-lead ECG will be performed.</outcome>
      <timepoint>Baseline and Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Heart rate - Cohort 2</outcome>
      <timepoint>Screening Through Week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood pressure - Cohort 2</outcome>
      <timepoint>Screening Through Week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of subjects with Adverse Events - Cohort 2 - The investigator will monitor each subject for clinical and laboratory evidence of adverse events.</outcome>
      <timepoint>Day 1 Through Week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Body temperature - Cohort 2</outcome>
      <timepoint>Screening Through Week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hematology - Cohort 2</outcome>
      <timepoint>Screening, Week 1, 2, 4, 6, and Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Chemistry - Cohort 2</outcome>
      <timepoint>Screening, Week 1, 2, 4, 6, and Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Physical Examination - Cohort 2 - Physical exam including body weight will be performed.</outcome>
      <timepoint>Screening, Week 1, 2, 4, 6, and Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Urinalysis - Cohort 2</outcome>
      <timepoint>Screening, Week 1, 2, 4, 6, and Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Electrocardiogram (ECG) - Cohort 2 - 12-lead ECG will be performed.</outcome>
      <timepoint>Baseline and Week 6</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subject has a solid tumor of a type likely or known to either overexpress wild-type
             Epidermal Growth Factor Receptor (EGFR) or to express variant III mutant EGFR (e.g.,
             head and neck squamous cell carcinoma, Non-small Cell Lung Carcinoma (NSCLC), and
             colorectal carcinoma).

          -  Subject must have disease that is not amenable to surgical resection or other approved
             therapeutic options with curative intent.

          -  Subject cannot tolerate or must not be eligible for other approved therapeutic options
             with known survival advantage.

          -  Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.

          -  Subject must have measurable disease as defined by Response Evaluation Criteria in
             Solid Tumors (RECIST) version 1.1 with at least 1 extrahepatic 2 cm lesion.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subject has received anticancer therapy including chemotherapy, immunotherapy,
             radiotherapy, hormonal, biologic, or any investigational therapy within a period of 14
             days prior to the first dose of ABT-806i.

          -  Subject has received a prior EGFR-directed monoclonal antibody within a period of 4
             weeks prior to the first dose of ABT-806i.

          -  Subject has unresolved clinically significant toxicities from prior anticancer
             therapy, defined as any Common Terminology Criteria for Adverse Events (CTCAE) Grade 2
             or higher.

          -  Subject has had major surgery within 21 days prior to the first dose of ABT-806i.

          -  Subject has a clinically significant uncontrolled condition(s) including but not
             limited to the following:

               -  Active uncontrolled infection

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris or cardiac arrhythmia

               -  Psychiatric illness/social situation that would limit compliance with the study
                  requirements</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>18</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Site Reference ID/Investigator# 52203 - Heidelberg</hospital>
    <hospital>Site Reference ID/Investigator# 58242 - Herston</hospital>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>4029 - Herston</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie (prior sponsor, Abbott)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is an open label study designed to evaluate the biodistribution and imaging
      characteristics of ABT-806i (111In-ABT-806) in subjects with advanced solid tumor types.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01472003</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Kyle D. Holen, MD</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>